Wonbiogen Co.,Ltd. Logo

Wonbiogen Co.,Ltd.

Develops and manufactures advanced wound care solutions and medical devices.

307280 | KO

Overview

Corporate Details

ISIN(s):
KR7307280008
LEI:
Country:
South Korea
Address:
경상북도 구미시 1공단로5길 56 ㈜원바이오젠, 구미시

Description

Wonbiogen Co., Ltd. is a company that develops, manufactures, and sells specialized medical devices and supplies. It focuses on the research and development of new medical bio-substances and highly biocompatible medical macromolecules to create advanced wound care solutions. The company's core product offerings consist of specialized wound dressings, including polyurethane foams, soft silicone adhesive dressings, and hydrocolloid spot patches. Its portfolio is marketed under brand names such as Medisorb and Renoderm, which are designed for various applications in wound protection and management.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2020-10-30 00:00
[기재정정]증권신고서(합병)
Korean HTML 3.1 MB
2020-10-29 00:00
분기보고서 (2020.09)
Korean HTML 441.9 KB
2020-10-29 00:00
[기재정정]분기보고서 (2020.09)
Korean HTML 452.0 KB
2020-10-21 00:00
[기재정정]주요사항보고서(회사합병결정)
Korean HTML 52.4 KB
2020-10-21 00:00
주주총회소집결의
Korean HTML 26.8 KB
2020-10-21 00:00
주주명부폐쇄기간또는기준일설정
Korean HTML 6.0 KB
2020-10-21 00:00
기업인수목적회사의임원선임결정
Korean HTML 12.7 KB
2020-10-21 00:00
기업인수목적회사의정관변경결정
Korean HTML 6.7 KB
2020-10-21 00:00
증권신고서(합병)
Korean HTML 2.7 MB
2020-10-15 00:00
주권매매거래정지해제(상장예비심사결과 통지(승인))
Korean HTML 4.3 KB
2020-08-07 00:00
주요사항보고서(회사합병결정)
Korean HTML 41.9 KB
2020-08-07 00:00
주권매매거래정지(SPAC 합병(예비심사청구대상))
Korean HTML 4.7 KB
2020-08-07 00:00
[기재정정]주요사항보고서(회사합병결정)
Korean HTML 44.7 KB
2020-08-05 00:00
반기보고서 (2020.06)
Korean HTML 424.0 KB
2020-05-14 00:00
분기보고서 (2020.03)
Korean HTML 413.7 KB

Automate Your Workflow. Get a real-time feed of all Wonbiogen Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Wonbiogen Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Wonbiogen Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.